Cassiopea S.p.A.
0
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy.
Show More
CEO
Mr. Pierpaolo Guzzo
Employees
11
Country
Germany
ISIN
IT0005108359
WKN
000A14U64
Listings
0 Comments
Share your thoughts
FAQs
What is Cassiopea S.p.A. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Cassiopea S.p.A. stocks are traded under the ticker CSP.MU.
How many employees does Cassiopea S.p.A. have?▼
As of November 1, 2026, the company has 11 employees.
In which sector is Cassiopea S.p.A. located?▼
Cassiopea S.p.A. operates in the Health & Wellness sector.
When did Cassiopea S.p.A. complete a stock split?▼
Cassiopea S.p.A. has not had any recent stock splits.
Where is Cassiopea S.p.A. headquartered?▼
Cassiopea S.p.A. is headquartered in Lainate, Germany.